INDEX

Abbreviations, 595–599
Abciximab, 444–445
Absorption (oral), 30–36, 93–96
active transport, 32, 601
amorphous and crystalline drug forms, 32, 212
diffusion, 32
food effect in animals, 73
fasting effect on transit time in humans, 107
formulation effects on, 13, 106–110, 210, 228–229, 314–315
in vitro models, 31
paracellular, 31–32
pH effects, 32
species prediction to humans, 109
transcellular passive diffusion, 31, 92
Accelerator mass spectrometry (AMS), 467, 475, 478–479
Accumulation index, 341–343
Acetaminophen (Tylenol), 209
Acetylsalicylic acid, 209
Active pharmaceutical ingredient (API), 14, 208, 216–220. See also Drug substance
inactive ingredients, 288, 560
micronization, 229
nomenclature system, 221–222
salt forms, 215, 217, 480
toxicology program, 286–288
toxicokinetics, 314–315
Acyl glucuronide(s), 46, 171, 319
ADME (absorption, distribution, metabolism and excretion), 14, 27–88
assays and screens, 68–73
CTD section, 575–579
desirable attributes, 28
druglike properties, 9
formulation effects, 225
in silico modeling and screens, 69, 70, 74–76
microdose studies, 477–478
oligonucleotides, 504–505
prioritizing assays, 68–69
Adverse drug reactions, see Enzyme inhibition
Allometric scaling, 112, 350–351
biopharmaceutics, 492
dose, 432–436
exposure, 434–435
intrinsic clearance, 436–437
microdose studies, 467
oligonucleotides, 505
Alzheimer’s disease, 4, 476
American Association of Laboratory Animal Science (AALAS), 379, 402
American Association of Pharmaceutical Scientists (AAPS), 133
American College of Clinical Pharmacology (ACCP), 477
Ames test, 19, 289, 295, 601
Analytical assays, 230–235
CMC section of CTD, 569–572
development and validation, 230–232
impurities, 231–232
specifications, 232–233

Early Drug Development: Strategies and Routes to First-in-Human Trials, Edited by Mitchell N. Cayen
Copyright © 2010 John Wiley & Sons, Inc.

617
stability, 233–234
toxicology support, 290–291
Animal models, 5
antibiotics, 13
dermatologicals, 13
 genetic knock-outs, 13
transgenic, 13
Antibiotics, see Drugs, antimicrobials
Anticoagulants (for plasma preparation), 135
Antibodies, 150–151, 495–496
neutralizing, 499
Anticancer agents
biopharmaceutics dose, 492
FIH starting dose, 434
FIH subjects, 448
highest nonsevere toxic dose (HNSTD), 304
product development plan, 514–515
toxicity studies, 293–294
Antigen, 150
Antihistamines, see Drugs, antihistamines
Anti-HIV drugs, see Drugs, anti-HIV
Argentina, 531–532
Aryl hydrocarbon receptor (AhR), 55
Aspirin, 8
Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), 402
AUC (area under the plasma/serum concentration/time curve) calculation, 333–336
definition, 333
toxicokinetics, 311, 329, 333
trapezoidal rule, 333–336
Australia
Clinical Trial Notification (CTN), 528–530
FIH trial, 528–530
FIH trial approval time, 545
Therapeutic Goods Administration (TGA), 17, 528–529
Autoinduction, 54, 316, 319
Benchmark dose (BMD), 430–431
Bepridil, 434
Beta-lactum antibiotics, 211
Bile excretion, 61–64, 319
Bioanalytical assays and studies, 15, 131–204
accelerator mass spectrometry (AMS), 467, 475
acceptance criteria, 173–174
accuracy, 157, 160, 161
archives, 390
biopharmaceutics, 132, 149–155, 168–169, 495–496
calibration standards (QCs) and curves, 166–167, 172
carryover, 147, 149, 391
chiral assay, 321
contamination, 391
control sample issues, 392
cross-validation, 169–170
Crystal City bioanalytical conferences, 132, 388, 392
discovery support, 188–189
documentation, 178–182, 188
extraction solvents and procedures, 137–139
EMEA and ICH role, 196–197
exploratory INDs, 471, 475–476
GLPs, 387–393
incurred sample reanalysis, 156, 174–176, 392
internal standard(s) (IS), 135, 167
ligand binding assays (for biopharmaceutics), 132, 135, 149–155, 168–169, 171
matrix effects, 147, 167, 168–169
microdose studies, 478–479
metabolite(s), 320–321
parallelism, 165–166
partial validation, 169–170
precision, 157, 161
protocol, 389–390
reproducibility, 161, 163
sample preparation, 133–139
selectivity, 161, 162, 168
sensitivity, 161–163
stability, 161, 163–165, 171, 173, 176–177
toxicology support, 290
validation, 156–167, 390
Bioavailability (oral), 6, 11, 15, 42
absolute, 480, 483
cassette-accelerated rapid rat screen (CARRS), 66–67
cassette dosing, 65
dose volume effects, 324
drug form effects, 219, 238–241, 480
exploratory INDs, 480
formulation effects, 210, 314–315
human prediction, 438–439
relationship to intersubject variability, 65
relationship to aqueous solubility, 220–221
Bioequivalence
  incurred sample reanalysis, 176
  prediction from solubility and dissolution data, 95–96

Biomarkers
  FIH trial, 16
  metabolomics, 77
  quantification, 146
  toxicity studies, 13

Biopharmaceutics, 489–511
  animal efficacy models, 491
  approval rates, 5
  boanalitical assays, 149–155, 168–169, 495–496
  "case-by-case" program design, 497–506
  cell therapies, 506
  CMC, 214–216
  development challenges, 10
  exploratory CTAs, 473
  FIH trial, 589–591
  flow-automated cell sorting (FACS), 496
  gene therapy, 501–504
  human specific, 491
  ICH S6 guideline, 250, 253, 284, 331, 426, 496–497
  immunogenicity, 331
  in vitro activity profiling, 491–492
  in vivo activity profiling, 492
  key product attributes, 490
  monoclonal antibodies, 497–498
  neutralizing antibodies, 499
  oligonucleotides, 505–506
  pharmacokinetics, 66, 498, 499
  production and manufacturing, 493–494, 507–508
  protein therapeutics, 498–501
  safety pharmacology, 278, 590
  selection considerations, 490–492
  species selection, 426–427
  superpharmacology, 13
  target identification, 8–9
  tissue distribution, 68
  toxicity, 13, 284, 426, 590
  toxicokinetcis, 331–332
  vaccines, 504–505

Biopharmaceutics Classification System (BCS), 92, 177

Biotransformation, see Metabolism

Bipolar disease, 4

Blood-brain barrier (BBB), 40–41
  in silico model, 75
  penetration in vitro, 40–41

Brain (and CNS)
  drug uptake, 40–41
  efflux transporters, 36

Brazil
  ANVISA (regulatory authority), 523
  clinical trials, 522–523

Caco-2 cell monolayers, see Permeability

Canada
  CTA, 527–528
  FIH submissions, 558
  FIH trial, 526–528
  FIH trial approval time, 545
  Health Canada, 17, 174–175, 388, 526–527

Carbamazepine (Tegretol), 57, 209, 218

Cardiac hERG channels, 11, 15
  effect of protein binding, 38, 71
  in silico model, 75
  study design, 254, 260–263

Cell therapies, 506

Central nervous system (CNS), 4
  safety pharmacology, 254

Certificate of analysis (CofA), 233, 287

Chemistry
  combinatorial synthesis, 14–15
  discovery support, 213
  medicinal, 284

Chemistry, manufacturing and controls (CMC), 14, 207–248, 565–574
  biopharmaceutics, 493–494, 507–508
  clinical trial application (CTA), 586–587
  CTD, 565–574
  discovery support, 208–209, 212–214
  exploratory IND support, 473–474
  FIH submissions and trial, 448–449, 553
  ICH guidances, 18
  impurities, 229–233
  IND requirements, 560, 565–574
  preformulation, 220–222
  pre-IND meeting, 565–566
  toxicology program, 210

China
  CTAs, 534–535
  clinical trials, 522
  FIH trial approval time, 545
  State Food and Drug Authority (SFDA), 534–535

Chirality, 11, 12

Cisapride, 97

Clearance, 42, 336–337
  allometric scaling, 112, 434–436
  calculation (intrinsic), 96
  calculation (plasma), 336–337
Clearance (Continued)
  enzyme inhibition impact, 48
  intrinsic, 45–46, 96, 436–437
Clinical hold, 564
Clinical trial application (CTA)
  China, 534–535
  clinical program, 523–526
  contents, 585–588
  Eastern Europe, 525–526
  European Union, 583–588
  guidelines, 584
  India, 535–537
  investigational medicinal product dossier (IMPD), 584–585
  Latin America, 530–534
  nonclinical sections, 587–588
  quality (CMC), 586–587
  toxicology program, 294
  United Kingdom, 524–525
Clinical Trial Exemption (CTX)
  Australia, 528–530
  Clinical trial material (CTM)
    CMC requirements, 229–236, 560
    shelf life, 234–235
    Cmax (maximum plasma/serum concentration)
      definition, 333
    toxicokinetics, 311, 329, 333
  Columbia, 532
Common Technical Document (CTD), 18, 520–521, 550–553
  Australia, 530
  Canada, 527
  CMC section, 566–574
    modules, 552, 562, 576
    nonclinical section, 575–580
    pharmacokinetics, 575–579
    pharmacology, 573–577, 579
    table of contents, 551
    toxicology, 575–580
  Constitutive androstane receptor (CAR), 55
  Consultants, 192–193
Contract Research Organizations (CROs), 6, 18–22, 28, 185, 192–193
  bioanalytical assay validation, 157, 177
  business partnership, 21
  CMC, 237–238
  crystal form analysis, 218
  documentation, 21
  FIH dossier, 555
  functions and activities, 19
  inspections and monitoring, 302–303
  selection, 20
  toxicology studies, 291, 296–298
  Critical path initiative (FDA): 465
  Crystallinity, see Physicochemical properties
  Cylert (pemoline), 17
  Cynomolgus monkey
    absorption similarity to human, 109
    cardiovascular safety pharmacology, 260, 265–266
    pharmacokinetic similarity to human, 109
  Cytochrome P450
    activation, 55, 57
    definition, 602
    enzyme inhibition, 15, 48–54
    expression in extrahepatic tissues, 92–93
    gender effects, 344
    inhibitors, 60, 99
    isozyme profiling, 57–61, 72
    mediation of drug-drug interactions, 47
    mediation of metabolism, 43, 97–98
    major human isoforms, 48, 97
    species differences, 318–319
    substrates, 98–99
  Cytotoxicity, 11, 241–244
Czech Republic
  CTA application, 525–526
  State Institute for Drug Control (SÚKL), 525–526
Decision tree (incl “go/no go”)
  ADME assays, 30, 69, 79
  enzyme inhibition, 49
  Diazepam, 476
  Digoxin, 105
  Dissolution rate, 30, 95, 106, 233
  Distribution, 36–42
    brain, 40–41, 322
    red blood cells, 317, 352–353
    tissues, 41–42, 321–322
  Dose, clinical
    MTD (maximum tolerated dose), 16
    Doxorubicin (adriamycin), 241–244
  Drug delivery, 13–14
  label, 7
  market withdrawals, 14, 16, 17, 113
  manufacturing site, 546
  potency, 9, 11
  selectivity, 9, 11
  Drug development
    attrition, 5–6, 9, 14, 29, 284
    definition, 12
    business perspectives, 4
    costs, 4, 28
    stages of, 244
  Drug discovery definition, 8
  Drug-drug interactions, 5, 11, 14, 29, 97–106
effect of protein binding, 38
metabolic, 47–57
pharmacodynamic, 47
pharmacokinetic, 47
prediction from in vitro drug transport assays, 104–106
prediction from in vitro enzyme induction, 101–104
prediction from in vitro enzyme inhibition, 54, 98–101
prediction from in vitro P-gp assays, 104–106
Drug product. See also Chemistry, manufacturing and controls
analytical, 571–572
biopharmaceutics, 493–494
CMC section of CTD, 566–574
definition, 220, 565, 602
excipients, 566, 570–571
impurities, 299–323, 560, 572
manufacture, 568–569
stability, 233–234, 573–574
Drug substance. See also Chemistry, manufacturing and controls
analytical, 571–572
availability, 14
characterization, 220–223
CMC section of CTD, 566–574
definition, 220, 565, 602
impurities, 221, 222–223, 299–323, 560, 566, 570, 571
manufacture, 229–230, 568–569
stability, 233–234, 573
Druggability, 8, 284
definition, 602
druglike properties, 9, 11
Drugs
anti-Alzheimer’s, 476
antihistamines, 113, 289
anti-HIV, 63
anti-inflammatory agents, 113
antimicrobials, 5, 113, 211, 323
arthritis, 5
cardiovascular, 5
CNS, 5, 355
ester stability, 171
generics, 4
oncology, 5, 113, 448
prokinetics, 113
statins, 113
Efflux transporters, 35–36, 38
effect of vehicle excipients, 316
Elderly, 49
Electronic
eCTD, 558–559
IND, 17–18
records and signatures, 403–408
FIH submissions, 557
Eli Lilly, 245
Enzyme-linked immunosorbent assays (ELISAs), 152–153
Enterocytes, 31
Enzyme induction
autoinduction, 316, 319
definition, 602
drug interaction prediction, 101–104
in vitro assays, 55–57, 102–103
IND submission, 578
lead optimization, 54–57, 71
probe substrates, 56, 102–103
Enzyme inhibition
adverse drug reactions, 49
autoinhibition, 316, 319
CYP2D6, 99–100
CYP2D6 and CYP3A4 in silico model, 75
definition, 602
drug interaction prediction, 53–54, 98–101
IND submission, 578
in vitro assays, 49–51
lead optimization, 11, 15, 48–54, 71
probe substrates, 52–53, 99
quinidine, 98
Environmental assessment, 554, 574
Epitope, 150
Erythromycin, 105, 476
EudraCT, 524
European Committee for Proprietary Medicinal Products (EC-CPMP/EFPIA), 17
European Medicines Agency (EMEA), 17, 196–197, 523
clinical trial application (CTA), see separate listing
FIH trial approval time, 545
marketing application, 523
European Union (EU)
Clinical Trials Database (EudraCT), 524, 584
FIH guidance documents, 554–555
independent ethics committee (IEC), 547, 583
investigational medicinal product dossier (IMPD), 584, 585
member countries, 523
Pharmacopeia, 561
Exantia (ximelagatran), 17
Exploratory INDs, 110, 195, 465–487. See also Exploratory CTAs; Microdose studies
advantages and disadvantages, 466, 481–484
Exploratory INDs (Continued)
backup compounds, 481
Belgium guidance (2007), 472–473
CMC support, 473–474
FDA guidance (2006), 465, 469–472
ideal candidates, 484–485
licensing strategy, 483
microdose studies, 466, 469–471, 475–479
nonclinical toxicity support, 469–472
pharmacological dose studies, 466, 470–472, 479–480
safety pharmacology support, 470–471
Exploratory CTAs, 465–487. See also Exploratory INDs biopharmaceutics, 472–473
EMEA microdose position paper (2004), 467
microdose studies, 467
toxicity support for microdose, 467–468
Excretion, 61–64, species differences, 319
Exposure multiples (animal/human) unbound fraction, 38
Felbamate, 57, 436
Fexofenadine, 105
First-in-human (FIH) submissions, 543–593. See also Investigational new drug submission (IND) approval times, 545
CRO role, 555
CTD, 550–553
document preparation, 557–559
formatting issues, 558
guidance documents, 554–555
project management, 553–557
QC review, 557, 558
reports, 557
First-in-human (FIH) trial, 15–16. See also First-in-human (FIH) submissions;
Investigational new drug application (IND) Australia, 528–530
biopharmaceutics, 589–591
Canada, 526–528
China, 534–535
CTA applications, 523–528
clinical trial material (CTM), 229–236
discipline partnerships, 448–450
dosage form prototypes, 226–228
dose escalation, 586
dose vehicle(s), 108
Eastern Europe, 525–526
Europe, 523–526
first-in-patient (FIP) trial, 549
formulation development, 224–229
global trials, 521–523
India, 535–537
Japan, 537–538, 588–589
Latin America, 530–534
metabolite(s), 320
objective(s), 16, 283, 450, 547
placebo dosage form, 235–236
regulatory submissions, 543–593
shelf life of CTM, 234–235
site selection, 546–548
starting dose, see Starting dose
stopping dose, 16, 250, 309–310, 351
subject selection, 448, 548–549
toxicokinetics role, 350–352
toxicology support, 294–295
United Kingdom, 523–525
First-pass elimination (presystemic metabolism), 42
extrahepatic tissues, 92
CMC role, 212–213
toxicokinetics, 315
Flow-automated cell sorting (FACS), 496
Fluvoxamine, 49
Food and Drug Administration (FDA), 17
Amendment Act of 2007, 16
collaboration with drug sponsors, 518–519
critical path initiative, 465, 468–469
drug approvals, 3–4
electronic records and signatures (21 CFR Part 11), 403
environmental assessment, 574
FD-483 citations, 21, 602
FIH guidance documents, 554–555
FIH trial approval time, 545
inspections, 399–401
pre-IND meetings, 518–519, 563–564
Type A meeting, 561, 564
Type B meeting, 561, 564
Type C meeting, 561, 564
Formulation, 13–14
dosing vehicles, 108
excipients, 316
exploratory IND evaluation, 480
effect on oral absorption, 107–110
goals, 13
G-protein-coupled receptors (GPCRs), 8
Gap analysis, 591–592
Gas chromatography (GC), 142–144
Gene therapy, see Biopharmaceutics
Genentech, 6
Generally regarded as safe (GRAS), 14
Generic drugs
Canada, 528
CTA application, 525
Genomics, 8, 603
Glutathione (and conjugates), 46
    glutathione-S-transferase, 92
    role in toxicity, 115
Good clinical practices (GCPs), 18, 521
    bioanalytical assay validation, 156
Japan, 538
Good laboratory practices (GLPs), 361–419
    archives, 385–387
    bioanalytical laboratory, 179, 183–188, 387–393
CROs, 363
    equipment, 377
    facilities, 376
    general provisions, 367–369
    hazard and risk, 363, 365–366
    history, 361–363, 395–396
    Japan, 396–397
    master schedule, 372–373
OECD GLP principles, 396–398
    personnel, 369–376
    principle investigator (OECD), 388
    principles, 362–365
    protocols, 373, 380–384, 413–416
    protocol deviations and amendments, 339, 373
    quality assurance unit (QAU), 371–374, 384, 399
    quality control (QC), 384
    raw data, 380–384, 399
    regulation 21 CFR part 58, 367, 394
    reports, 385–387
    safety pharmacology, 250
    SOPs, 370, 373, 378, 392, 408–411
    study director, see Study director
    study sponsor, 398
    test and control articles, 379–380
    testing facilities operations, 377–379
    toxicity studies, 10, 12, 287, 289, 293–304
    toxicokinetics, 312
Good manufacturing practices (GMPs; also cGMPs), 18, 222, 230, 287, 379–380, 586
Guidances (and guidelines). See also Regulations
Belgium exploratory INDs (2007), 472–473
efficacy (ICH), 18
EMEA control sample contamination (2005), 392
EMEA CMC (2004), 554
    drug interactions (2006), 47
EMEA FIH study (2007), 427, 428–429, 554, 584–586, 589
EMEA microdose position paper (2004), 467
EU CTA Eudralex Vol 10 (2005), 584
FDA bioanalytical (2001), 132, 156, 157, 170, 389
FDA environmental assessments (1995), 554, 574
FDA guidance definition, 18
FDA drug interaction (2006), 47, 53, 55, 57, 100
FDA exploratory INDs (2006), 465, 469–472
FDA FIH starting dose (2005), 350, 427
FDA IND content and format (1995), 519–510, 554, 575
FDA IND meetings (2001), 554
FDA in vitro metabolism (1997), 42, 47
FDA metabolite safety (2008), 193, 289, 318
FDA meetings with sponsors (2000), 554
FDA out-of-specifications (OOS) (2006), 178
FDA single dose toxicity (1996), 467
Health Canada bioavailability (1992, 1996), 388
ICH E6 GCPs and IB, 550, 581
ICH M2 electronic CTD, 550, 558
ICH M4 Common Technical Document (CTD), 550–553, 561, 565
ICH Q2b impurities (2006), 287
ICH S1A/S1B carcinogenicity (1996–1998), 295, 346
ICH S1C carcinogenicity dose selection (1995), 346
ICH S2(R1) genotoxicity testing (2008), 295, 346
ICH S4 single dose toxicity (1991), 346
ICH S4A chronic toxicity duration (1999), 295, 346
ICH S5A reproductive toxicity (1995), 346
ICH S5B male fertility (2000), 346
ICH S6 nonclinical safety of biopharmaceuticals (1997), 250, 253, 284, 331, 426, 495–497, 550, 589
ICH S7A safety pharmacology (2001), 250, 253, 278, 346, 347–348
ICH S7B QT prolongation (2005), 251, 260, 278, 346
ICH S7E quality (ICH), 18
    safety (ICH), 18
Half-life, 43
definition and calculation, 336
number to reach steady state, 342
Health Canada, see Canada

Hepatocytes
  biliary excretion assay, 61
  enzyme induction, 55–57, 102–103
  intrinsic clearance 45–46
  metabolism and stability, 70, 288
  toxicity in vitro, 115

High-performance liquid chromatography, 136–137, 139–142, 232

High-throughput techniques
  ADME assays, 29–30
  chemical synthesis, 14–15
  enzyme inhibition, 49–52
  liver microsomal metabolism, 43–44
  toxicogenomics, 13

Hismanal (astemizole), 14

Hit confirmation, 10

Hit-to-lead identification, 9–10, 19

Human equivalent dose (HED), 428, 431–436

Hydroxypropyl-ß-cyclodextrin (HPßCD), 108, 212, 225

IC_{50}, 100

Idiosyncratic drug reaction
  definition, 603
  toxicity, 113, 115–117

Immunogenicity, 150, 499

Impurities
  analytical assays, 231–232
  drug substance and drug product, 229–233
  FIH batch, 560
  ICH Q3b guidance (2006), 287
  toxicity qualification, 219, 222, 287

IND, see Investigational new drug application

India
  Central Drugs Standard Control Organization (CDSCO), 535–537
  clinical trials, 521, 522, 535–537
  Drug Controller General, 197–198
  FIH trial approval time, 545

Indinavir (Crixivan), 209, 238–241

Inhibition rate constant (K_{i}), 53, 100

Interferon
  antibody formation, 499

International Conference on Harmonisation (ICH), 549–553, See also Guidelines formation, 17
  members, 17

Intravenous, see Parenteral administration

Investigational new drug application (IND), 559–583
  clinical section, 580–583
  CMC section, 560, 565–574
  content and format, 519–521, 559–563
  electronic, 17–18, 558
  environmental assessment, 554, 574
  FDA form 1571, 559–560
  investigator’s brochure (IB), 580–583
  nonclinical section, 574–580
  pre-IND meeting, 305–306, 518–519, 563–564
  project management, 553–557
  reports, 561
  submissions, 543–593
  toxicology summary, 561

Investigator’s brochure (IB), 545
  content, 575, 580–583
  guidance, 581
  table of contents, 582
  timeline, 556

Institutional review board (IRB), 15, 447, 547
  regulation 21 CFR part 56, 554

Itraconazole, 212, 225

Japan
  clinical trial protocol notification (CTPN), 588
  clinical trials, 537–538
  FIH trial approval time, 545
  ICH guidelines, 538
  Ministry of Health, Labor and Welfare (MHLW), 17, 197, 537–538
  NOAEL, 588
  Pharmaceutical Manufacturers Association, 17
  Pharmaceuticals and Medical Devices Agency (PMDA), 588
  pharmacopeia, 561

Ketoconazole, 58, 99, 100, 105

Ketoconazole, 58, 99, 100, 105

Laboratory information management system (LIMS), 155, 178–182, 186–188

Latin America
  Clinical Trial Applications, 530–534
  clinical trials, 522–523
  LC-MS/MS (and LC-MS)
    bioanalytical assays, 133, 140–149, 154–156
    discovery support, 189
    Caco-2 cell assay, 33
    CRO support, 20
    high throughput in vivo assays, 65–66
    in vitro assays, 29, 43–44, 98
    metabolite(s), 320
    species selection for toxicity studies, 289

Lead optimization, 7, 9–12,
  ADME strategies, 27–88
CRO collaboration, 19
definition, 603
formulation, 13
pharmacokinetics, 27–88, 120
toxicology function, 284
Lipophilicity. See also Lipinski rule of five
definition, 603
effect on ADME, 74
effect on blood-brain barrier, 40
effect on permeability, 92
effect on pharmacokinetics, 106
lead optimization considerations, 9, 10, 11
Lipinski rule of five, 9, 69, 93–94, 177
Lipitor (atorvastatin), 5, 218
MABEL, see Minimal anticipated biologic effect level
MALDI (matrix-assisted laser
desorption/ionization), 135
Maximum tolerated dose (MTD)
carcinogenicity studies, 349
definition, 603
toxicity studies, 285, 304
Mean residence time (MRT), 337
Mechanism of action, 249
exploratory INDs and CTAs, 472
Meetings, see Food and Drug Administration Merck, 6
Metabolism, 42–61, 97–104
gender effects, 322–323, 343
in vitro techniques, 42–61, 97–104, 288–289
isozyme profiling, 57–61
metabolic stability, 42–46, 70, 75
liver microsomal assay, 43–44, 288
phase 1 metabolism, 43, 288
phase 2 metabolism, 43, 288
Metabolites
characterization and identification, 46–47
bioanalytical in discovery support, 188–189
enzyme induction impact, 54
enzyme inhibition impact, 48
exploratory IND evaluation, 480
human specific, 47
metabolites in safety testing (MIST), 193–194, 317–321
of prodrugs, 133
pharmacological activity, 15, 47
phase 2 (conjugates), 319–320
pre-FIH evaluation, 193–194
reactive (metabolites and intermediates), 46, 113, 319, 605
stability, 171
toxicity, 46, 289
toxicokinetics, 314
Metabolomics, 76–78, 117–118, 603
Metabonomics, 117–118, 604
Microdose studies, 428, 445–446
bioanalytical, 475–476
CREAM trial, 476, 478
definition, 466, 467
EMEA position paper (2004), 467–468
FDA guidance (2006), 469–471
Japanese initiative, 477
pros and cons, 476–479
Microsomes, 42–45
Midazolam, 476
Minimal anticipated biologic effect level
(MABEL)
CTA, 586
safety margin, 331, 354
starting dose (FIH) estimation, 428, 590
Mode of action, 249
Monoclonal antibodies. See also TGN 1412
pharmacokinetics, 498
receptor distribution, 497–498
toxicity, 430, 497–498
Moxifloxacin, 436
Multiplexed inlet system (MIX), 33
Myozyme, 500–501
New drug application (NDA)
505(b)1 NDA, 514
505(b)2 NDA, 514
timeline strategies, 7
No observable effect level (NOEL), 304, 310, 604
No observed adverse effect level (NOAEL)
CTA, 586
definition, 285, 429, 604
interpretation, 303–304
Japanese criteria, 588
safety margin establishment, 310, 350–352
starting dose estimation, 427–431
Oligonucleotides, 505–506
Oncology, 4
Organization for Economic Cooperation and Development (OECD), 196,
GLPs, 375–377, 385–386, 396–398
member countries, 396
Oxycodone, 98
P-glycoprotein, 11, 35–36, 38, 63, 104–106
Parenteral administration
intramuscular, 227
intravenous, 227, 241, 316, 330, 336
subcutaneous, 227
INDEX

Parkinson’s disease, 4
Patents
- protection, 4, 11
- expiration, 4
Penicillin, 8
Permax (pergolide), 17
Permeability, 15, 95
- absorption effect, 30
- Caco-2 cell monolayers, 31, 32–35, 70, 75, 94–95
- bioavailability prediction, 92
Personnel
- bioanalytical laboratory, 183, 185–186
- clinical site, 547
- CMC, 213
- GLPs, 363–365; 369–376
Pfizer, 6
Pharmacokinetics (PK), 14, 64–68, 72–73, 333–337
- accumulation index, 341–343
- allometric scaling
- CTD section, 575–579
- dose proportionality
- food effect in animals, 73
- formulation effects on, 14, 107–110, 316
- microdose studies, 478
- multiple dosing, 315–316
- noncompartmental kinetic parameters, 333–337
- oligonucleotides, 505–506
- physicochemical property effects on, 214
- prediction for humans, 72, 91–113
- prediction from in silico methods, 112–113
- “rapid rat” screen, 189
- study timing, 65
- variability, 548
Pharmacokinetics-pharmacodynamic (PK/PD) relationships
- bioanalytical assays, 157
Pharmacology, See also Safety pharmacology
- basic principle, 6
- CTD section, 575–579
Pharmacopeias
- content, 565, 604
- Europe, 561
- Japan, 561
- United States, 561
Pharmaceutical Research and Manufacturers Association (PhRMA) (USA), 17, 394
Phenobarbital, 103
Physicochemical (or pharmaceutical) properties, See also Lipophilicity; Solubility
- bioanalytical assay sample preparation, 133
- CMC linkage, 209–212
- crystal polymorphism, 216–217
- crystallinity, 209, 211, 212, 215, 217–220
- log P, 31, 74
- pKa, 31
- molecular weight, 31
Physiologically based pharmacokinetic (PBPK) models, 110–112, 440
PK-PD relationships
- animal models, 66
- FIH starting dose estimation, 351, 427
- metabolite role, 47
- Plavix (clopidogrel bisulfate), 5
- Polymerase chain reaction (PCR), 503
Polymorphism
- crystallinity, 216–220
- cytochrome P450 2D6, 99–100
- definition, 604
Portfolio management, 6–7. See also Project management
- Posicor (mibefradil), 14
- Positron-emission tomography (PET), 467, 475, 476
- Pregnane X receptor (PXR), 55, 71, 104, 105
- Pre-IND meetings, 304–305, 518–519
- Prodrugs
- activation, 54
- bioanalytical assays, 133, 171
- doxorubicin peptide conjugate, 241–244
- chemical stability, 211
- Product development plan, 513–515. See also Project management
- Product label, 513
- Project management and collaboration, 21, 513–541. See also Decision tree
- clinical, 195–196
- CMC, 208–209, 212–213
- development plan, 513–515
- FDA input, 518–519
- FIH dose selection, 427, 448–450
- FIH submissions, 553–557
- gap analysis, 591–592
- medicinal chemistry, 284
- product development plan, 513–515
- project teams, 14
- regulatory questions, 592
- time management, 516
- toxicology, 284–286
- Proof-of-concept (POC), 5, 7
- Protein binding, 12, 15, 36, 38–39, 71
- clinical relevance, 38–39
- equilibrium dialysis, 38
impact on intrinsic clearance, 96
IND submission, 578
in silico model, 75
toxicokinetics, 352–353
ultracentrifugation, 38
ultrafiltration, 38
volume of distribution estimation, 438–439
warfarin, 38
Protein kinases, 8
Protein therapeutics, see Biopharmaceutics
Proteomics, 604
Protocols
amendments, 300–302
analytical stability, 234
CROs, 21
deviations, 301–302, 339
FIH study, 556, 575, 580
toxicology studies, 291, 292, 295–302
Quality assurance (QA), 19, 183, 187
GLP regulations, 366, 371–374, 384
Quality control (QC)
bioanalytical laboratory, 187
bioanalytical standards, 158–159, 164–167, 172
FIH submissions, 557, 558
GLPs, 366, 384
Quinidine, 98, 99
QT prolongation, 58, 267
Racemates, 11, 194, 321. See also Chirality
enantiomer interconversion, 321
Radioimmunoassay (RIA), 152, 154, 168
Radiolabeled compounds, 46, 61, 193, 195, 320
Ranitidine (Zantac), 218
Rate constant, 336
Raw data, see GLPs
Reaction phenotyping, 57
Receptor(s)
-binding, 19
-nuclear, 55
Regulations
FDA test and control articles, 21 CFR pt 58, sec 105: 222, 223
FDA electronic records, 21 CFR part 11: 363, 403–408
FDA GLPs, 21 CFR part 58: 367, 554
FDA cGMPs, 21 CFR parts 210 and 211: 230, 232
FDA IRBs, 21 CFR part 56: 554
FDA protection of human subjects, 21 CFR part 50: 554
Japanese MHLW GLPs, 396
OECD GLPs, 375, 396, 554
Prescription Drug User Fee Act (PDUFA), 518–519
Reports
bioanalytical validation, 180–182
Rifampin, 105
Ritonavir (Norvir), 218
Roche, 6
Rozerem (remelteon), 49
Risk/benefit ratio, 4, 16
Russian clinical trials, 522
Safety (human)
chimeric mouse model, 117
predictions from ex vivo animal studies, 117–119
predictions from in silico methods/software programs, 119–120
predictions from in vitro models, 114–116
predictions from in vivo animal studies, 116–117
Safety margins (animal/human exposure multiples), 350–355
calculation, 285, 310, 316
gender effects, 322–323
interpretation, 353–355
unbound fraction, 312
Safety pharmacology, 11, 249–280
biopharmaceutics, 278, 590
cardiovascular, 254–267, 271–272
CNS, 254, 275–276
exploratory IND support, 470–471
gastrointestinal, 274–276
hemodynamic effects, 260, 264–266
IND submission, 576–577
Irwin’s test, 254, 255–260
ocular, 277
pharmacokinetics/toxicokinetics, 253–254, 329, 347–348
renal, 274–275
respiratory, 267–273
timing, 252–254
Salts, see Active pharmaceutical ingredient
Sandwich-cultured rat hepatocyte assay, 61–64
Scaling, see Allometric scaling
Schering-Plough, 6
Screening IND, 467
Sertraline (Zoloft), 218
Schizophrenia, 4
Society of Quality Assurance (SQA), 394
Solubility
aqueous, 5, 30, 70, 92, 106, 210, 215
crystalline drug forms, 219–220
in GI tract, 106–107
pH dependence, 214, 221
Species
selection for safety pharmacology, 260, 262, 273, 274
selection for toxicity studies, 13, 47, 66, 288–289, 310
St.John’s wort, 105
Stability
bioanalytical assay validation, 161, 163–165
chemical, 6, 11, 12, 210, 215
degradation products, 211, 224
ester drugs, 171
metabolic, 6, 11
Standard operating procedures (SOPs)
bioanalytical assay validation, 156, 175, 183–184
CROs, 21
toxicity studies, 302
Starting dose (for FIH trial), 16, 423–463
ADME relevance, 425
anticancer drugs, 304, 432
based on allometric scaling, 432–437
based on animal MTD, 116
based on body mass, 432–433
based on MABEL, 428, 440–445
based on animal NOAEL, 303, 428–431
based on pharmacologically active dose (PAD), 440–445
based on safety margins, 309–310, 350–352, 431–432
based on safety pharmacology, 250
biotherapeutics, 445, 455–456
case studies, 451–458
discipline coordination, 427
exploratory INDs and CTAs, 472
guidance documents, 427, 428–429, 440
human equivalent dose (HED), 428, 431–434
IND submission, 576
PK/PD relationships, 351, 427
toxicological considerations, 446–448
Statins, 211
Statistics
dose proportionality, 340
toxicokinetic data, 338
Steady state, 341–343
Stopping dose, see FIH trial
exploratory INDs, 472
Stravudine, 436
Structure-activity relationships (SAR), 10, 44, 46
Study director
definition, 399, 605
GLP requirement, 187, 368
multisite studies, 375
responsibilities, 295–296, 370–371, 381, 411–413
Study plans and monographs
bioanalytical assay validation, 156–157
clinical, 286
pharmaceutical evaluation, 214–215
Sulfabutyl-ß-cyclodextrin
Synthesis
metabolite(s), 47
radiolabeled drugs, 46
scale-up, 14
Target identification, 8–9, 19, 27
Terfenadine, 57–58, 97, 100
Test article, 398
TGN 1412, 440, 441–445, 473, 490, 508–509
regulatory impact, 546
Theophylline, 110
Therapeutic index, 58, 304, 605
Title 21 CFR, see Regulations
\( t_{\text{max}} \) (time to peak plasma/serum concentration)
definition, 333
toxicokinetics, 311, 329, 333
Topiramate, 436
Torsades de pointes, 252, 260
Toxicity and toxicology (studies), 283–307.
See also GLPs
acute, 12, 295
API considerations, 286–288
AUC values, 285. See also Toxicokinetics
biomarkers, 447
biopharmaceutics, 284, 426, 430, 494, 501, 590
carcinogenicity, 287, 289–290
cardiovascular, human, 113
chromosomal aberration, 295
clastogenicity (chromosomal aberration), 289, 295, 602
clinical study plan role, 286
chronic, 12
CTD section, 575–580
DEREK program (genotoxicity), 247
discovery support, 284–285
dose level, 379
dose ranging and selection, 292–293, 295, 323–324
drug formulations and drug form change, 219, 223
drug formulation, 223–224
drug synthesis, 222–223
INDEX

exploratory IND, 285
European trials, 294
fertility, 295
FIH dose impact, 429–434
FIH trial excipient qualification, 225
formulation development, 223–224
genetic toxicology, 289–290
genotoxicity, 287, 288
goal of pre-FIH studies, 222
human toxicity relevance, 425, 446–448
idiosyncratic, 113, 115–117
immunogenicity challenges, 499
impurity qualification, 219, 222, 287
institutional animal care and use committee
(IACUC), 402
in vitro approaches, 114–116
laboratory animals, 402
liver, human, 113
maximum tolerated dose (MTD), 285, 292, 304
metabolites, 289, 317–321
micronucleus assay, 295, 604
mutagenicity (DNA damage), 289, 604
no observed adverse effect level (NOAEL), 285, 292, 303–304, 427–431
oligonucleotides, 505–506
pilot studies, 292–293
prediction for human, 113–120
principal investigator, 296
protocols, 295–302, 380–384, 413–416
recovery phase, 292, 293–294
reproduction, 295
safety pharmacology interpretation, 250
species selection, 288–289, 293, 313–314
study director, 294–296, 411–413
study duration, 294–295
timelines to FIH trial, 556
tissue examination, 303
vehicles for oral dosing, 223–224, 316
study costs, 332
study designs, 312–332
study duration, 294–295

Toxicogenetics, 118, 605
Toxicogenomics, 13, 118, 605
Toxicokinetics, 15, 309–359. See also Safety
margins

accumulation, 341
API properties, 314–315
bioanalytical validation, 156, 316–317
biopharmaceutics, 331–332, 495
bleeding times, 292–293, 324–331
blood sampling sites, 325–326
blood volume, 324–325
bridging toxicity studies, 350
carcinogenicity studies, 349–350
chronic studies, 347
data analysis, 332–339
definition, 605
dose limiting absorption, 315
dose proportionality, 340–341
dose range finding studies, 346–347
drug supply, 312–313
gender, 322–323, 343–344
genetic toxicity studies, 348
GLPs, 312
historical perspectives, 310–311
interpretation, 339–345
LC-MS/MS, 311
metabolites, 314, 317–321
multiple dosing, 341–343
number of animals, 322
parameters, 311–312
physiologically based modeling, 338–339
protein binding, 312, 352–353
purpose, 310
red blood cell (RBC) partitioning, 352–353
reproductive toxicity studies, 348–349
safety margins, 350–355
safety pharmacology studies, 253–254, 347–348
serial sampling, 326–327
single dose, 346
sparse sampling, 327–328
species selection, 313–314
steady state, 342
study costs, 332
study designs, 312–322
toxicity studies, 299, 345–350
urine, 322
Transcriptomics, 118, 605
Transporters, 35–37, 104–107. See also
P-glycoprotein
ATP-binding cassette (ABC) transporter
proteins, 104
active, 9
membrane, 11
solute carrier transport (SLC) proteins, 104
species specificity, 319
Trasylol (aprotinin), 17
Troglitizone, 115, 436
UDP-glucuronosyltransferase superfamilies, 92
United Kingdom
CTA requirements, 524–525
Gene Therapy Advisory Committee, 525
MHRA, 524
United States (USA). See also FDA; IND
Pharmacopeia, 561
INDEX

630

Vaccines, 504–505
Venlafaxine, 436
Vioxx (rofecoxib), 16, 17
Volume of distribution, 42
calculation, 337
prediction in human, 438–439

Warfarin, 476
Web sites, 613–615

bioanalytical, 134–135
pharmacopeias, 561
Wyeth, 6
Xelnorm (tegaserod), 17
Xenosensors, 55

Zenarestat, 436
Zonisamide, 436